We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed at $280.19 in the latest trading session, marking a -1.22% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.45%.
The stock of world's largest biotech drugmaker has fallen by 1.59% in the past month, lagging the Medical sector's gain of 5.47% and the S&P 500's gain of 3.07%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. In that report, analysts expect Amgen to post earnings of $5.01 per share. This would mark a year-over-year decline of 10.22%. Alongside, our most recent consensus estimate is anticipating revenue of $8.93 billion, indicating a 5.04% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $21.1 per share and a revenue of $35.62 billion, signifying shifts of +6.35% and +6.58%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.54% higher. Amgen is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Amgen is currently being traded at a Forward P/E ratio of 13.44. This denotes a discount relative to the industry average Forward P/E of 22.21.
We can also see that AMGN currently has a PEG ratio of 2.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.75.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 93, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Amgen (AMGN - Free Report) closed at $280.19 in the latest trading session, marking a -1.22% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.45%.
The stock of world's largest biotech drugmaker has fallen by 1.59% in the past month, lagging the Medical sector's gain of 5.47% and the S&P 500's gain of 3.07%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. In that report, analysts expect Amgen to post earnings of $5.01 per share. This would mark a year-over-year decline of 10.22%. Alongside, our most recent consensus estimate is anticipating revenue of $8.93 billion, indicating a 5.04% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $21.1 per share and a revenue of $35.62 billion, signifying shifts of +6.35% and +6.58%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.54% higher. Amgen is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Amgen is currently being traded at a Forward P/E ratio of 13.44. This denotes a discount relative to the industry average Forward P/E of 22.21.
We can also see that AMGN currently has a PEG ratio of 2.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.75.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 93, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.